Journal
BMC IMMUNOLOGY
Volume 21, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12865-020-00365-w
Keywords
Baricitinib; GM-CSF; IL-1 beta; Janus kinases; Rheumatoid arthritis; Tofacitinib; Upadacitinib
Categories
Funding
- Eli Lilly Japan K.K.
Ask authors/readers for more resources
Background Innate immune cells play a crucial role in the pathophysiology of rheumatoid arthritis (RA) via release of cytokines. Small-molecule inhibitors of Janus kinases (JAKi) are clinically efficacious in patients with RA. However, the isoform-specific action of each JAKi is difficult to assess, since JAKs form heterodimeric complexes with cytokine receptors. We assessed the effects of several JAKi on GM-CSF-primed human innate immune cells. Results Treatment with JAKi (tofacitinib, baricitinib, upadacitinib) prevented GM-CSF-induced JAK2/STAT5 phosphorylation at higher concentrations (400 nM) in THP-1 cells. Whereas compared with baricitinib or upadacitinib, the inhibitory effects of tofacitinib on the GM-CSF-induced JAK2/STAT5 phosphorylation were weak at lower concentrations (<= 100 nM). All JAKi inhibited GM-CSF-induced IL-1 beta production by human neutrophils. However, the inhibitory effects of baricitinib on IL-1 beta production were larger compared to those of tofacitinib or upadacitinib at lower concentrations (<= 100 nM). Similarly, all JAKi inhibited GM-CSF-induced caspase-1(p20) production by human neutrophils. Conclusion We conclude that incubation with JAKi prevents GM-CSF-mediated JAK2/STAT5 activation in human innate immune cells. Although baricitinib and upadacitinib almost completely blocked GM-CSF-mediated JAK2/STAT5 signaling, the inhibitory effects of tofacitinib were weaker at lower concentrations suggesting that variation exists among these JAKi in the inhibition of JAK2 signaling pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available